| Review: |
The radiotracers used in Positon Emission Tomography (PET) are different from conventional nuclear medicine pharmaceuticals. They have extremely short lives and therefore have to be produced very close to the clinical user. The busy and demanding nature of the clinical settings for PET adds to the complexities and leads to the need for more robust quality management programmes. This book looks at clinical settings for PET, raising awareness of the issues involved and looking at how to minimize risk. There are chapters on: the translation of PET research into clinical practice; oversight committees; terminology; and types of automated systems. There are also chapters laying out management systems for: strategies and practice to reduce risks of error in the final product; validation; and criteria for acceptance for PET synthesis. The latest PET tracers are also described. |